Information CCG-222740 CCG-222740 is a Rho/MRTF pathway inhibitor. CCG-222740 decreases the activation of stellate cells in vitro and in vivo, by reducing the levels of alpha smooth muscle actin(α-SMA) expression. Targets Rho ; α-SMA In vitro CCG-222740 increases the protein levels of p27 and decreased cyclin D1. CCG-222740 treatment decreased cell viability of CAFs, with an IC50 of~10 μM, as measured by the MTT assay. In pancreatic cancer, CAFs are one of the main producers of matrix proteins, including several collagen isoforms. The Rho/MRTF pathway inhibitor CCG-222740 decreases the levels of collagens I, 2a and IV, as well as α-SMA in the CAFsIn cancer cells. CCG-222740 treatment leads to the exclusion of MRTF from the nucleus. . In vivo CCG-222740 significantly reduces α-SMA levels in the pancreas of caerulein- stimulated KC mice. Cell Research(from reference) Cell lines：Cancer associated fibroblasts (CAFs) Concentrations：10 μM and 20 μM Incubation Time：72 hours
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
CCG-222740
CAS number：1922098-69-8 molecular formula：C23H19ClF2N2O3
overview
compound introduction
Specs
| Chinese alias | - | ||
| English alias | 3-Piperidinecarboxamide,N-(4-chlorophenyl)-5,5-difluoro-1-[3-(2-furanyl)benzoyl]- | ||
| CAS number | 1922098-69-8 | molecular formula | C23H19ClF2N2O3 |
| molecular weight | 444.86 g/mol | Exact mass | 10mM in DMSO |
| PSA | 62.600 Ų | logp | 3.99 |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
